ArticleProceedings of the National Academy of Sciences of the United States of America2025
Erasable serum markers.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Monitoring in vivo transcription with synthetic serum markers.Nature communications · 2026Article
- Synthetic serum markers enable noninvasive monitoring of gene expression in primate brains.Neuron · 2026Article
- Research on Monitoring Exercise-Induced Fatigue Through Infrared Thermal Imaging and Surface Electromyography: A Pilot Study.Journal of functional morphology and kinesiology · 2026Article
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
Gene expression in the brain is typically evaluated using invasive biopsy or postmortem histology. Serum markers provide an alternative way to monitor the brain, but relatively few such markers exist. Additionally, the origin of serum markers often cannot be localized to a specific cell population, and monitoring dynamic changes in their gene expression is compromised by the same factor that makes the markers detectable-long serum half-life. Here, we propose a paradigm to improve the sensitivity of serum marker measurement by modifying them with an external chemical stimulus. As a proof of concept, we use a well-controlled system with known half-life and tunable serum levels. This system, released markers of activity (RMA), or RMAs enables measurement of transgene expression in the brain through a simple blood test. RMAs are stable in blood, with a half-life of >100 h and can detect expression from as few as 12 neurons in mice. However, their long serum half-life also generates detectable background signals when RMA are used to track temporal changes in gene expression. By engineering on-demand erasable RMAs and injecting an intravenous targeted protease, we reduced RMA background signal by more than an order of magnitude without compromising the detection sensitivity. Similarly to previous RMA iterations, our approach showed a 65,000-fold increase in their signal over the baseline when expressed in a single brain region but also improved the dynamic range of detection for low-level promoter activity that is driven by physiological levels of c-Fos.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.